Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9580528 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CA2NPSR1TSHRMAPK1 | |
| SCHEMBL9778093 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CA2NPSR1TSHRMAPK1 | |
| SCHEMBL31399323 | 0.89 | ALDH1A1 (0.45) | ALDH1A1CA2NPSR1TSHRMAPK1 | |
| SCHEMBL408541 | 0.85 | ALDH1A1 (0.41) | ALDH1A1CA2 | |
| SCHEMBL11932963 | 0.84 | ALDH1A1 (0.41) | ALDH1A1CA2 | |
| SCHEMBL11023633 | 0.83 | ALDH1A1 (0.41) | ALDH1A1CA2NPSR1 | |
| SCHEMBL7875753 | 0.83 | CA2 (0.59) | ALDH1A1CA2NPSR1TSHRMAPK1 | |
| SCHEMBL8372855 | 0.82 | ALDH1A1 (0.51) | ALDH1A1CA2 | |
| SCHEMBL14822031 | 0.82 | ALDH1A1 (0.51) | ALDH1A1CA2TSHRMAPK1 | |
| SCHEMBL14822336 | 0.82 | ALDH1A1 (0.51) | ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4028384-A | HYDROSILYLATION WITH A HYDROGEN SILANE, PLATINUM COMPLEX CATALYST | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1977-06-07 | — | — | US | claimed |
| US-20260034106-A1 | Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics | UNIV DARMSTADT TECH (DE) | 2026-02-05 | — | — | US | disclosed |
| EP-4686495-A1 | MACROCYCLIC LIGANDS FOR FK506-BINDING PROTEINS FOR TREATMENT OF DISEASES WITH IMPROVED CHARACTERISTICS | Technische Universität Darmstadt (DE) | 2026-02-04 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-6413543-B1 | DRUG DELIVERY | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-02 | — | — | US | disclosed |
| EP-0880530-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1998-12-02 | — | — | EP | disclosed |
| EP-0408219-B1 | Method of treating textiles | DOW CORNING (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0408219-A2 | Method of treating textiles | DOW CORNING CORPORATION (US) | 1991-01-16 | — | — | EP | disclosed |
| US-4954269-A | TREATING TEXTILES TO INCREASE THE WATER ABSORPTIVITY | DOW CORNING CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4908228-A | Dioxolane, diol and diacrylate silicon compounds and method for their preparation and use | DOW CORNING CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0306802-A1 | Chiral crown ethers | MILES INC. (US) | 1989-03-15 | — | — | EP | disclosed |
| EP-0266895-A2 | Dioxolane, diol and diacrylate silicon compounds and method for their preparation and use | DOW CORNING CORPORATION (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4028384-A | HYDROSILYLATION WITH A HYDROGEN SILANE, PLATINUM COMPLEX CATALYST | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1977-06-07 | — | — | US | disclosed |
| US-3950364-A | PROCESS FOR THE PREPARATION OF ORGANIC SILICON COMPOUNDS | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 641/4885CA2 4674/4885NPSR1 4573/4885 |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | ALDH1A1 641/4885CA2 4674/4885NPSR1 4573/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 641/4885CA2 4674/4885NPSR1 4573/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 641/4885CA2 4674/4885NPSR1 4573/4885 |
| US-20260034106-A1 | Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics | FKBP3, FKBP2, FKBP1B | ALDH1A1 4381/4885CA2 1894/4885NPSR1 158/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 641/4885CA2 4674/4885NPSR1 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.